A Phase 1, Randomized, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of CC-93538 in Healthy Japanese and Caucasian Adult Subjects
Latest Information Update: 04 Nov 2021
At a glance
- Drugs Cendakimab (Primary)
- Indications Eosinophilic oesophagitis
- Focus Pharmacokinetics
- Sponsors Celgene Corporation
- 20 Aug 2020 Status changed from not yet recruiting to completed.
- 24 Sep 2019 New trial record